Katarzyna Pitorowska-Radziewicz - Deputy Minister of Health, Poland (inv)

Stephan Eder - President, Medicines for Europe and Executive Vice President Western Europe & Germany, STADA
Stephan Eder has more than 15 years of experience in the healthcare industry. He has been a member of STADA's global management team since 2020 and is responsible for Western European markets, including Germany. Before joining STADA, Stephan Eder held various international management positions at Novartis, Sandoz and Hexal.

Olivér Várhelyi - Commissioner, Health and Food Safety, European Commission (inv)

Frank Vandenbroucke - Deputy Prime Minister and Minister of Social Affairs and Public Health, Belgium (inv)

Frank Vandenbroucke (Leuven, 21 October 1955) grew up in a family of doctors. From a strong social and scientific commitment, he chose to study economics. In 1978, he obtained a licentiate in economics from the KU Leuven, followed by a Master of Philosophy in Economics from the University of Cambridge in 1982. In 1996, he obtained his doctorate from the University of Oxford with a dissertation in the field of social and political philosophy. His political career began in 1985, when he became a member of parliament in the House of Representatives. Four years later, he was elected party chairman of the SP, a position he held until 1994. In the following years, he held various ministerial posts in federal and Flemish governments:

Deputy Prime Minister and Minister of Foreign Affairs (1994-1995)
Minister of Social Affairs and Pensions (1999-2003)
Minister of Work and Pensions (2003-2004)
Deputy Prime Minister and Minister of Education and Employment (2004-2009)

He then devoted himself entirely to academia. In 2011, Frank Vandenbroucke was appointed professor at KU Leuven. In 2015, he was appointed university professor at the University of Amsterdam. He focuses on research and debate on the social significance of the European Union.

In October 2020, he returned to politics as Deputy Prime Minister and Minister of Social Affairs and Public Health in the federal government. In 2025 he will be reappointed to this position, with additional responsibility for poverty reduction.

Katerina Patavou - Head of European Public Affairs, Panhellenic Union of Pharmaceutical Industries

Katerina Patavou, currently is the Head of European Public Affairs and Social Impact Strategist for the Panhellenic Union of Pharmaceutical Industries (PEF), a national association member of Medicines for Europe, representing 55 member companies that manufacture medicines and operate in Greece. Her role at PEF encompasses both national and European level engagement on policy developments and corporate advocacy. In 2025, she was elected Vice-Chair of the National Association Committee of Medicines for Europe. With over 12 years of European public affairs experience, policy analysis, national implementation and strategic advocacy in the healthcare sector, coupled with her legal background, she has a thorough understanding of the European legislative ecosystem. She is a graduate from the University of Reading with a bachelor degree in Law (LLB) and a Masters in EU Law from Kings College London. She finessed her business acumen during her tenure at several Brussels based consultancies after working as accredited assistant at the European Parliament.

Representative of the European Commission (TBC)

Thomas Courbe - Director General, French Ministry of Industry of Directorate-General for Enterprise

Elisabeth Stampa - Chair at Medichem SA and Vice President at Medicines for Europe

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently as Chair at the Board of Medichem SA and member of the Board at Catalonia Health (health cluster of > 240 companies). She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. Elisabeth held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.

Alexandra Moulson - Chief Excellence Officer and Managing Director, Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in drug development, portfolio management, and commercial strategy. She has over 25 years of experience in pharmaceuticals and has worked in biosimilars since 2010. Alex is British, with Biochemistry and MBA degrees. Following her MBA, Alex spent 6 years at McKinsey leaving as an Associate Principal, 2 years at Morphosys in Business Development and joined Sandoz in 2010. At Sandoz Alex was responsible for bringing a rituximab biosimilar to the EU and Japanese markets. She later led the Strategy Department for Sandoz. She joined Polpharma Biologics in 2019 and has held various positions including Chief Development Office and Chief Strategy and Portfolio Officer.

Karolina Nowak - *D*irector of Innovation and Biotechnology Development Department, Medical Research Agency, Poland

Dr Karolina Nowak is director of the Department of Innovation and International Cooperation in Medical Research Agency. She was a visiting scientist at Harvard Medical School, Dana-Farber Cancer Institute. She received a prestigious scholarship at Stanford University and did an Internship at Stanford Biomaterials and Advanced Drug Delivery Laboratory. Doctor Nowak is a graduate of Executive MBA at ESG University of Quebec at Montreal and Warsaw School of Economics. She is a patent inventor of new pharmaceutical drug formulation dedicated for patients with alveolar osteitis and she was a scientist in the field of Pharmaceuticals, drug formulations and molecular biology. She has participated in numerous national and international projects. Beside her scientific activities she has experience in managing 2 commercial projects in area of drug development.

Dries Pattyn, Country Manager, Sandoz (inv)

Julie Maréchal-Jamil - Sr Director Pharmaceutical Policy, Medicines for Europe
Member of the Biosimilars Committee, International Generic and Biosimilar medicines Association (IGBA)

Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objective of the Biosimilar Medicines Group is to support and facilitate the design, evolution and implementation of policies aimed at fostering greater access to biologic therapies and other healthcare products and services, with biosimilar medicines use as catalyst for smart investment and innovation in health. Since 2015, she has been actively involved, including in leadership positions, in the IGBA Biosimilars Committee activities contributing to Global policy discussions. Her knowledge and understanding of the scientific, regulatory, pharmaceutical and health policy environments at EU and global levels, greatly supports her effective engagement with all the players involved in the EU and global ecosystems. Part of the Medicines for Europe Management Team, she is responsible for People & Organisation matters, focused on employees' professional growth. With a MSc in Pharmacology, she previously worked in the pharmaceutical industry.

Erik Bogsch - Biosimilar Business Unit Director, Gedeon Richter, Hungary

Dr. Erik Bogsch is the Head of the Biotechnology Business Unit at Gedeon Richter Plc (GR). The Biotechnology Business Unit covers all activities GR conducts within the biotechnology space, including development, manufacture and

commercialisation of biosimilars in addition to CDMO activities. Erik has a PhD in Cell Biology and his research interests were in the area of protein transfer processes. He is the author of multiple scientific publications. Erik has worked in both the food and pharmaceutical business' in multiple geographies and has filled positions primarily in Development, but also in Manufacturing and Quality. He has been working for Gedeon Richter Plc. since 2012. As Director of the Biotechnology Business Unit he is responsible for the development, production and business strategy of biotechnology-based medicines within the Company.

Jean-Marc Bourez - CEO, European Institute of Innovation and Technology (EIT) Health

Adrian van den Hoven - Director General, Medicines for Europe

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the Chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).

Bastiaan Venhuis - Senior Policy Advisor at the Department of Pharmaceuticals and Medical Technology, The Netherlands

Dr. Bastiaan Venhuis is a Dutch expert on sustainable healthcare and the environmental impact of pharmaceuticals. As a senior policy advisor at the Ministry of Health, Welfare and Sport (VWS) he focusses on green procurement, green pharmacy and environmental legislations. Dr. Venhuis has worked on many aspects in the pharmaceutical product lifecycle including drug design, clinical trials and market authorisation. In 2016 he started contributing to the Dutch Chain Approach on medicines residues in water. He has co-authored several reports and papers about medicines use and risks to the environment. The Dutch Ministry of VWS recognizes that medicines' residues are a burden to the environment and to the production of drinking water. The Netherlands advocates an integral approach, involving the industry sector, healthcare sector and water sector to effectively address the challenges.

Mona Arnold - Principal Scientist, (Tech Lic., MBA), VTT Technical Research Centre ltd

Ms Mona Arnold (Tech Lic., MBA) has +20 years of professional experience in innovation and R&D management in national and international projects relating to environmental technologies and environmental affairs. She is especially acknowledged in sustainable businesses, resource sufficiency, circular economy processes, EU waste and water policy tools and the twin transition. In VTT, she is currently working as principal investigator in the team Sustainable Business Models with responsibility on solutions for circular economy and digital transformation. Ms Arnold has been responsible for a preliminary Finnish study on the costs of implementing the revised urban wastewater directive with regards to micropollutants and is also actively engaged in the EU Horizon project Imermaid, which creates innovative solutions for the management of chemicals of emerging concern.

Richard Bergström - Vice-President European Affairs, IQVIA

Richard Bergström is a pharmacist by training. He received his MScPharm degree from the University of Uppsala, Sweden in 1988 and his honorary doctor title in October 2022. After his first job at the Swedish Medicines Agency, he worked for 10 years in regulatory affairs at global and EU level at Roche and Novartis in Basel. For 15 years he was a lobbyist for pharma leading the industry associations in Sweden (LIF) and later in Brussels (EFPIA). During the pandemic he was the vaccine coordinator for the Swedish government and effectively seconded to the European Commission (DG SANTE/HERA) as member of the EU Joint Negotiation Team. In September 2022 he joined IQVIA as Vice President European Affairs based in Switzerland. He is also a member of the Board of European Health Forum Gastein, the Board of Trustees of EUPATI, and served for six years as vice chair of the Karolinska Institute.

Steffen Saltofte - CEO, Zentiva

Steffen Saltofte is a passionate and focused leader with an exceptional track record in strategic growth. He serves as the CEO of Zentiva Group, where he leads a dedicated team of 5,000 associates across more than 30 countries, committed to delivering high-quality and affordable medicines globally. His leadership is marked by a strong commitment to sustainability and the creation of a dynamic corporate culture. Steffen's career spans various senior executive roles. Steffen joined from Acino where he was CEO, prior to that he has held key positions at Boehringer Ingelheim, Merial (a Sanofi Company), Syngenta, and Maersk Line, where he demonstrated his expertise in global commercial operations, business development, and change management. Steffen holds an MBA from IMD and bachelor's degrees in International Business and Strategic Market Management from Copenhagen Business School, as well as a Bachelor's in Shipping from the Institute of Chartered Shipbrokers. Fluent in Danish and English, with proficiency in Swedish and

German, Steffen brings a global perspective to his leadership approach. Under his guidance, Zentiva continues to thrive as a leader in the pharmaceutical industry in Europe, delivering on its promise of accessible healthcare while fostering a culture of innovation and excellence. Steffen's dedication to sustainability and quality ensures that Zentiva remains at the forefront of the industry and providing health and wellbeing to more than 100 million people in Europe and beyond.

Alexandra Polcher, Senior Managing Consultant - Environment & Health, RambollAlexandra Polcher is a Senior Managing Consultant in Ramboll's Environment & Health practice. With over 20 years of experience, she leads projects addressing environmental and health challenges across Europe. Her strong professional and academic background as food chemist equips her with deep expertise in risk assessment, toxicological evaluation of chemical substances, and exposure analysis. Alexandra has successfully delivered numerous projects for both industry and public-sector clients, focusing on providing robust scientific evidence to support informed decision-making. Collaborating with a multidisciplinary team of experts, she regularly engages with emerging policy issues. Earlier this year, she and her team conducted a comprehensive literature review on micropollutants in wastewater.

Arnaud Mahéas - Chair of Generic Market Access Committee, Medicines for Europe, Head Public Affairs Europe, Sandoz Arnaud is the Head of Public Affairs Europe at Sandoz. He is responsible for public and government affairs at the EU and national levels in more than 40 countries. His focus is to expand patient access, regain pricing flexibility, promote smart procurement and resilient supply for generic and biosimilar medicines. Since 2023, he chairs the Generic Medicines Market Access Committee at Medicines for Europe. Arnaud is a highly experienced public affairs professional with a successful track record across multiple industries. He built and led the European public affairs practice at Servier. And prior to joining the healthcare industry 15 years ago, he headed the EU representation of the French national railway company (SNCF) and later managed strategic relations with the EU for the association of the top 100 companies operating in France (AFEP). Arnaud holds a Master of Arts in European Administration and Politics from the College of Europe in Bruges and degrees in European Law and Government Affairs from the University of Rennes and Sciences Po Rennes.

Laure Geslin - Team Leader, European Commission's Directorate-General for Health and Food Safety (DG SANTE) (inv)

Laure Geslin is Policy Officer at the European Commission's Directorate-General for Health and Food Safety (DG SANTE). She is leading a team focused on EU level policy developments related to the accessibility, affordability, and availability of medicines, and is responsible for steering EU-wide cooperation in relation to pricing and reimbursement of medicines. Prior to this role, Laure served as Head of Division for Proper Use at the Belgian Federal Agency for Medicines and Health Products (FAMHP), where she chaired the Belgian Task Force for Medicines Shortages and represented the agency in the EMA/HMA Task Force on Availability of Authorised Medicines and the Belgian Pricing Committee for Pharmaceutical Products. She previously worked as Director of Tarification Services and Professional Development and Defence at Pharmacy. Brussels, and advocated for community pharmacists in Brussels. Laure started her career as community pharmacist and holds a Master's degree in Pharmaceutical Science from the University of Ghent, Belgium.

Michal Nitka - *Senior Vice* President Generics Head Europe & OTC Global Head, Teva

Michal Nitka is senior vice president generics head Europe & OTC global head at Teva since September 2024. Nitka has 30 years of experience in the pharmaceutical industry, including senior leadership roles at Teva and other top companies, with expertise in generics, biosimilars, EU markets, and healthcare systems. He is a medical doctor by training and holds postgraduate degrees in marketing and management from the University of Łódź, the Chartered Institute of Marketing, along with executive development programs IMD Lausanne.

Artur Cwiok - Head of Europe and Canada, Viatris

With over three decades of experience in the pharmaceutical industry, Dr. Artur Cwiok is a dynamic leader dedicated to shaping the healthcare landscape through strategic vision and innovation. A qualified physician with an extensive background in the pharmaceutical sector, Dr. Cwiok has held senior leadership roles across Europe, driving success across multiple channels—from generics to branded medicines, OTC to prescription, and retail to hospital settings. His expertise spans mature and innovative therapies, consistently delivering results that enhance patient access and industry growth. As Head of Europe and Canada at Viatris, a global healthcare company operating in 38 European countries and reaching over 165 countries worldwide, Dr. Cwiok is committed to ensuring access to high-quality medicines. A passionate advocate for universal healthcare, he actively contributes to national and regional industry associations, championing policies that remove barriers to essential treatments. As a Member of the Executive

Committee for Medicines for Europe, Dr. Cwiok plays a key role in shaping the future of healthcare, striving to make optimal health attainable for all. His unwavering dedication to improving lives fuels the mission to empower people to live healthier at every stage of life.

Paul Tredwell - Executive Vice President, Accord Healthcare

Paul has over 25 years' experience in the pharmaceutical industry, predominantly on the speciality and biosimilar side of the business. On biosimilars Paul was the first to fully commercialise 3 biosimilars in a regulated market, collaboratively setting up the Biosimilar division of BGMA and acting as Vice Chair. Paul joined Accord in 2018, where he led the strategy of Accord's Speciality Brands division, playing a significant role in helping Accord to be one of the biggest suppliers of oncology medicines in Europe. Paul's pharma experience includes UK, Europe and Global management roles in commercial, business development and general management positions. Since July 2021, Paul has led Accord's operations in the EMENA territory, with responsibility for implementing and delivering the company's mission to increase access to high quality medicines within the region with an exceptional pipeline of generic, biosimilar and novel medicines and is responsible for a turnover of $1bn with over 2000 employees.

Walter Van Dyck - Full Professor and Partner, Vlerick Business School

Maeve Hynes - Pharmacist - Procurement, Health Service Executive (HSE) (inv)

David Jauch - Vice President Governmental Affairs & Public Policy, Fresenius

David M. Jauch is responsible for Government Affairs and Public Policy at Fresenius. In the past he held positions of Market Access, Government Affairs and Corporate Social Responsibility (CSR) at Fresenius Kabi. He is the Chair of the Public Affairs Group, Member of the Board of Medicines for Europe as well as a member of the Trade Committee of IGBA (International Generics and Biosimilar Association) and has been working in the pharmaceutical industry for more than 10 years. David studied Business Administration at the University of Stuttgart in Germany, Tongji University in Shanghai, China and Seoul National University in Korea and holds an Executive master's in business management of Leeds University Business School in the UK.

Benedetta Baldini - *Senior* Health Policy Advisor, ESIP

Benedetta Baldini is Senior Health Policy Advisor at the European Social Insurance Platform (ESIP), the umbrella organisation bringing together 46 national statutory social security institutions from 18 EU Member States and Switzerland. Since 2020, Benedetta Baldini is in charge of European health policies at ESIP and represents statutory healthcare payers and pricing and reimbursement authorities in Brussels. She leads ESIP's work on several policy files, such as the EU general pharmaceutical package, the Critical Medicines Act, the upcoming Biotech Act, the European Health Data Space, with a strong advocacy-oriented focus. She also supports the coordination of MEDEV, an informal network of 25 national authorities from 20 EU Member States and Norway bringing together all the relevant institutions responsible for the assessment, pricing and reimbursement of medicines in Europe. Benedetta is part of several health policy networks: the European Commission-led eHealth and Beating Cancer Stakeholder Groups, the HTA Stakeholder Network, the Critical Medicines Alliance, the WHO/Europe Novel Medicines Platform, the Young Forum Gastein network and the informal IPSE network – Italiani per le Politiche Sanitarie Europee. Prior to joining ESIP, Benedetta worked in the context of European social policies. Interpreter by training, Benedetta also holds a Master in political communication and international affairs. An Italian national, she is fluent in Italian, English and French.
@BBaldini16 & @esip_eu

Anca Toma - Executive Director, EPF (inv)

Prof. Roisín O'Hare - PGCHET BSc(hons) MSc DPharm FSPNI (IP) FHEA FFRPS FRPS, NI Lead Clinical Education Pharmacist, NI Universities Network, Director of Professional Development, European Association of Hospital Pharmacists (EAHP)

Roisín has been a clinical pharmacist working in a hospital environment for over 20 years and she has been a teacher, in various guises, for almost as long. She completed her Doctorate in pharmacy practice in 2014, evaluating the introduction of OSCEs into Queen's University Belfast and has published a book on this topic. Roisín is a Fellow of the Royal Pharmaceutical Society of Great Britain and the Pharmaceutical Society of Northern Ireland as well as the UK Higher Education Authority. She is currently working on her Consultant Pharmacist portfolio. Roisín was one of the first independent prescribers in Northern Ireland (NI), establishing pharmacist-led clinics to manage patients with pulmonary hypertension and heart failure. Since 2008, Roisín has led the NI Universities Clinical Education Pharmacist Team, who are based across hospital Trusts and both Schools of Pharmacy in NI. She works with multi-professional colleagues across the Faculties in both UU and QUB to develop clinical skills for colleagues including in simulated environments. Roisín is not only passionate about education development but also the future of the Pharmacy profession. She is an active member of the GPhC Initial Education and Review board providing practical insights to the development of a future career path for pharmacists, including prescribing in the undergraduate degree. Roisín has also been actively involved with the Guild of Healthcare Pharmacists (GHP) throughout her career and more recently, in 2024, joined both the Board of the European Association of Hospital Pharmacists (EAHP) and the Scientific Committee, bringing her interest in advocacy and education to support the development of hospital pharmacy teams across Europe.

Lucas Sigman - Chair, IGBA´s CEO Advisory Committee, Member of the Medicines for Europe's Executive Committee and Chief Executive Officer, Insud Pharma S.L.

Lucas Sigman has a degree in Biology from the University of Buenos Aires and an MBA from the IESE business school. With more than 20 years of experience, he directs an international group with a presence in more than 50 countries, 20 production plants and more than 9,000 professionals. Between 2014 and 2020 he was Managing Director of the Chemo business unit within the Insud group, developing significant experience in various areas of the industry: R&D; Production, Commercial and Portfolio. From 2020 he is Insud Pharma CEO. In addition, Lucas is a speaker and collaborator in different industry forums. He is member of the board of AESEG, the Spanish Association of Generic Medicines and is a patron of the Mundo Sano Foundation, dedicated to neglected diseases, in which he actively collaborates.

Theodore E. Tryfon, President of PEF, co-CEO of ELPEN Group and Member of the Executive of Medicines for Europe

Theodore E. Tryfon was born in Mytilini – Lesvos. He graduated from Athens College of Greece and earned his BSc in Economics and Business Administration from the University of Southampton in UK. He continued his studies by earning an MBA from City University of London Business School. In 1992 he joined Elpen Pharmaceutical Co. and presently is the Vice President and co CEO of ELPEN Group. In 2024, ELPEN Group had a turnover of 430,000,000€. Since 2023, in addition to the three productions units at Pikermi, Attikis, ELPEN also operates a new 12,000 m2 Development and Manufacturing facility in Keratea, Attikis.. Currently the Group is occupying more than 1.600 employees in Greece and abroad. ELPEN holds a leading position in the pharmaceutical market, exporting to over 90 countries and has the largest Research, Training and Experimental Center of the Greek Pharmaceutical Industry. Since 2014, Mr. Tryfon has been elected as President of the Panhellenic Union of Pharmaceutical Industries (PEF), an association which represents 49 companies with 45 production sites throughout Greece. In 2019 he became a Member of the Board of the Hellenic Federation of Enterprises (SEV) as well as a Member of the Board of Directors of Medicines for Europe, the European Association representing the European Generic and Value Added Medicines Industry.

Markus Sieger - CEO, Polpharma Group

Markus Sieger has been active in emerging markets and emerging industries for over 30 years. During this time, he has focused on building and developing companies in the pharmaceutical, media, fast-moving consumer goods and real estate industries, by managing complex and strategic transactions in the USA, CEE, CIS and Singapore. He has been a member of supervisory boards of private and public companies and is currently on a board member of Rafael Holdings

(NYSE:RFL). He has been associated with Polpharma Group since 2000 and was appointed CEO of Polpharma Group in June 2016. In 2018, he joined the Executive Committee of Medicines for Europe. He is an alumnus of Stanford University Graduate School of Business.